SCHEMBL18189479

SCHEMBL18189479

CC(C)Oc1ccc(Cl)cc1-c1ccc2c(c1)CC(=O)N2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 2/20 0.56
▸ PGR P06401 1/20 0.54
▸ GRIA1 P42261 5/20 0.50
▸ CACNG8 Q8WXS5 3/20 0.50
▸ SCN9A Q15858 1/20 0.46
▸ CMA1 P23946 1/20 0.46
▸ MDM2 Q00987 1/20 0.45
▸ PDE3B Q13370 1/20 0.45
▸ PDE3A Q14432 1/20 0.45
▸ BRD4 O60885 2/20 0.44
▸ TDP2 O95551 2/20 0.44
▸ OTUD7B Q6GQQ9 1/20 0.43
▸ KDM5B Q9UGL1 1/20 0.43
▸ CREBBP Q92793 1/20 0.42
▸ FGFR1 P11362 1/20 0.42
▸ FGFR2 P21802 1/20 0.42
▸ FGFR3 P22607 1/20 0.42
▸ BMPR1B O00238 1/20 0.42
▸ BMPR1A P36894 1/20 0.42
▸ TGFBR1 P36897 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18189661 0.83 KIF11 (0.51) GRIA1CACNG8PDE3BPDE3ABRD4
SCHEMBL18189503 0.82 GRIA1 (0.55) AHRPGRGRIA1CACNG8PDE3B
SCHEMBL18189364 0.80 GRIA1 (0.68) AHRPGRGRIA1CACNG8CMA1
SCHEMBL18189562 0.79 AHR (0.69) AHRPGRGRIA1CACNG8CMA1
SCHEMBL18189408 0.78 GRIA1 (0.55) AHRPGRGRIA1CACNG8PDE3B
SCHEMBL14920030 0.77 AHR (0.65) AHRPGRGRIA1CACNG8CMA1
SCHEMBL1900155 0.76 AHR (0.77) AHRPGRGRIA1CACNG8CMA1
SCHEMBL18189599 0.75 GRIA1 (0.52) PGRGRIA1CACNG8PDE3BPDE3A
SCHEMBL154614 0.74 AHR (1.00) AHRPGRGRIA1CACNG8CMA1
SCHEMBL18190578 0.73 TP53 (0.46) GRIA1CACNG8SCN9AMDM2PDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107750250-B Indolone compounds and their use as AMPA receptor modulators 詹森药业有限公司 2021-09-07 — — CN claimed
US-10604484-B2 Indolone compounds and their use as AMPA receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2020-03-31 — — US claimed
EP-3288935-B1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-10-30 — — EP claimed
US-20180118683-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 — — US claimed
EP-3288935-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2018-03-07 — — EP claimed
WO-2016176463-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2016-11-03 — — WO claimed
CN-107750250-B Indolone compounds and their use as AMPA receptor modulators 詹森药业有限公司 2021-09-07 — — CN disclosed
US-10604484-B2 Indolone compounds and their use as AMPA receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2020-03-31 — — US disclosed
US-10604484-B2 Indolone compounds and their use as AMPA receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2020-03-31 — — US disclosed
EP-3288935-B1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-10-30 — — EP disclosed
US-20180118683-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 — — US disclosed
US-20180118683-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 — — US disclosed
US-20180118683-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 — — US disclosed
EP-3288935-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2018-03-07 — — EP disclosed
WO-2016176463-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2016-11-03 — — WO disclosed
WO-2016176463-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2016-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10604484-B2 Indolone compounds and their use as AMPA receptor modulators GRIN3A, GRIN1, GRIN2B AHR 509/4885PGR 587/4885GRIA1 23/4885
US-20180118683-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS GRIN3A, GRIN1, GRIN2B AHR 509/4885PGR 587/4885GRIA1 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback